Fundamental Analysis of LINEAGE CELL THERAPEUTICS IN(NYSEARCA:LCTX) stock

Fundamental Rating

LCTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. Both the profitability and financial health of LCTX have multiple concerns. LCTX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

LCTX had negative earnings in the past year.

In the past year LCTX has reported a negative cash flow from operations.

In the past 5 years LCTX always reported negative net income.

In the past 5 years LCTX reported 4 times negative operating cash flow.

1.2 Ratios

LCTX has a better Return On Assets (-23.53%) than 74.51% of its industry peers.

LCTX has a Return On Equity of -35.41%. This is in the better half of the industry: LCTX outperforms 76.11% of its industry peers.

		Industry Rank	Sector Rank
ROA	-23.53%
ROE	-35.41%
ROIC	N/A

ROA(3y)-22.39%

ROA(5y)-19.13%

ROE(3y)-38.79%

ROE(5y)-29.64%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 90.82%, LCTX belongs to the best of the industry, outperforming 92.87% of the companies in the same industry.

In the last couple of years the Gross Margin of LCTX has remained more or less at the same level.

LCTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	90.82%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y5.54%

GM growth 5Y-0.32%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LCTX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, LCTX has more shares outstanding

The number of shares outstanding for LCTX has been increased compared to 5 years ago.

The debt/assets ratio for LCTX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -3.77, we must say that LCTX is in the distress zone and has some risk of bankruptcy.

LCTX's Altman-Z score of -3.77 is in line compared to the rest of the industry. LCTX outperforms 44.74% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that LCTX is not too dependend on debt financing.

LCTX's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. LCTX outperforms 49.02% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-3.77

ROIC/WACCN/A

WACC10.4%

2.3 Liquidity

A Current Ratio of 2.64 indicates that LCTX has no problem at all paying its short term obligations.

The Current ratio of LCTX (2.64) is worse than 69.16% of its industry peers.

LCTX has a Quick Ratio of 2.64. This indicates that LCTX is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of LCTX (2.64) is worse than 68.09% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.64
Quick Ratio	2.64

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.69% over the past year.

The Revenue for LCTX has decreased by -39.15% in the past year. This is quite bad

The Revenue has been growing by 12.38% on average over the past years. This is quite good.

EPS 1Y (TTM)7.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%50%

Revenue 1Y (TTM)-39.15%

Revenue growth 3Y69.71%

Revenue growth 5Y12.38%

Sales Q2Q%203.37%

3.2 Future

The Earnings Per Share is expected to decrease by -0.40% on average over the next years.

Based on estimates for the next years, LCTX will show a very strong growth in Revenue. The Revenue will grow by 74.13% on average per year.

EPS Next Y-2%

EPS Next 2Y-7.28%

EPS Next 3Y-7.88%

EPS Next 5Y-0.4%

Revenue Next Year-45.06%

Revenue Next 2Y10.82%

Revenue Next 3Y38.45%

Revenue Next 5Y74.13%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LCTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year LCTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as LCTX's earnings are expected to decrease with -7.88% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-7.28%

EPS Next 3Y-7.88%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LCTX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LINEAGE CELL THERAPEUTICS IN

NYSEARCA:LCTX (11/21/2024, 1:52:54 PM)

0.6022

-0.04 (-5.91%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap113.72M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-23.53%
ROE	-35.41%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	90.82%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.64
Quick Ratio	2.64
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)7.69%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-2%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-39.15%

Revenue growth 3Y69.71%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

LINEAGE CELL THERAPEUTICS IN (LCTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens